Hims & Hers vs PlushCare
All-in cost at every dose, fee structure, care model, pharmacy disclosure and terms — compared on one basis.
Only Hims & Hers publishes a price we could capture ($2,388 for a first year at a maintenance dose). The other does not, so this comparison cannot be settled on cost.
What can be compared is what each discloses: visit model, pharmacy identity, laboratory requirement and cancellation terms. Those are below.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
Hims & Hers vs PlushCare at every dose
A single headline figure assumes a maintenance dose neither you nor your prescriber has chosen yet. This is the same comparison at all six strengths.
Hims & Hers against PlushCare at every dose
| Dose | Hims & Hers | PlushCare | Cheaper |
|---|---|---|---|
| 0.25 mg | $199 | — | — |
| 0.5 mg | $199 | — | — |
| 1 mg | $199 | — | — |
| 1.7 mg | $199 | — | — |
| 2.4 mg | $199 | — | — |
What differs beyond price
Price is the easiest thing to compare and rarely the thing that decides satisfaction. These are the attributes each programme publishes.
| Attribute | Hims & Hers | PlushCare |
|---|---|---|
| Pricing model | flat at every dose | model unknown |
| Membership | none | none |
| Prepaid rate | none published | none published |
| Visit model | async | not published |
| Labs | optional | not published |
| Pharmacy disclosure | brand only since Mar 2026 | not published |
| Cancellation | membership recurring | not published |
| Regulatory status | compounded, not FDA-approved | FDA-approved |
| Evidence status | third-party figure | no price published |
Which one, for whom
If you want the lowest total cost: neither can be ranked on cost until both publish a price.
If you want budget certainty: Hims & Hers, which holds one price at every strength.
If you want to verify the supply chain: neither names a dispensing pharmacy in a way we could verify — ask both directly.
If you may need to stop early: compare the cancellation rows above before prepaying. Compounded medication is generally not refundable once it has shipped, so a multi-month term is the wrong structure during titration, when intolerance is the most likely reason to stop.
Switching between them
Usually possible after a clinical review, and the two real risks are a supply gap while a new intake is processed and a new prescriber restarting titration rather than continuing your dose. Confirm dose continuity in writing before cancelling anything, because a month back at 0.25 mg is a month of lost progress no price difference recovers.
Fee structure, side by side
Hims & Hers charges no recurring fee on top of medication. PlushCare charges no recurring fee.
This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.
Care model and what it buys
Hims & Hers: async, labs optional, included. PlushCare: visit model not published, labs not published, coaching not published.
Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.
Verification, which outranks both
Hims & Hers: brand only since Mar 2026. PlushCare: pharmacy not disclosed.
A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.
What can still be decided here
Without a price on both sides this cannot be settled on cost, so it has to be settled on what each programme publishes — which is frequently the better basis anyway.
Hims & Hers publishes: visit model async, laboratory requirement optional, pharmacy brand only since Mar 2026, cancellation membership recurring. PlushCare publishes: visit model not stated, laboratory requirement not stated, pharmacy not stated, cancellation not stated.
A programme publishing four of those and one publishing none are not equally knowable, and that asymmetry is a finding rather than a gap in our research. Ask both for the total at 2.4 mg including every fee, in writing, and see which answers.
Why a missing price is itself information
A programme that publishes its price is making a claim it can be held to. A programme that reveals cost only after an intake has made a commercial choice: it wants your contact details and a medical history before you can compare it against anything.
That is legal and common. It is also why several pages on this site carry an explanation instead of a number. Estimating would mean inventing the only figure that matters, and every time we have checked an estimate published elsewhere against a provider's own page, the estimate was low.
Putting hims & hers and plushcare in proportion
It is one input into a decision with three parts: what you pay at the dose you hold, who makes what you inject, and what happens if you stop. Weighting one to the exclusion of the others is how people end up on a cheap programme they abandon in month nine.
The frame: 20 programmes publish a capturable price, spanning $145 to $324 a month all-in at a 2.4 mg maintenance dose. 4 charge a mandatory recurring fee. 6 name the dispensing pharmacy before purchase.
What good looks like
A figure at a named dose, the pharmacy named, cancellation terms published before payment, and a plain statement that a compounded preparation is not FDA-approved. Four things, all cheap to publish, and a minority does all four.
The cheapest verified route sits at $145 a month, which establishes that disclosure and low price are not in tension.
What to ask before you pay
Five questions, all answerable in a short email, all before a medical history changes hands: the total at a maintenance dose including every fee; which pharmacy fills it; whether the prescriber is licensed in your state; the notice period to cancel and what is refundable; and which form of the active ingredient the pharmacy compounds from.
None requires clinical training to evaluate. The speed and specificity of the reply tells you how the operation is run, and it arrives before your money does.
The failure mode this section guards against
Choosing a programme on a number that describes a different situation than yours. An entry price when you will hold maintenance. A medication figure when a membership applies. A promotional rate when you will renew.
Each error is small alone and they compound in one direction, which is why the cheapest-looking option in most published comparisons is the one most likely to be mis-stated. Priced correctly the cheapest verified route sits at $145 a month all-in at a 2.4 mg maintenance dose.
Why we publish the working rather than a verdict
A single recommendation reads better and acts worse, because it hides the weighting. Two readers with different maintenance doses, different coverage and different tolerance for commitment should not receive the same answer.
So the tables carry the inputs and every ranking states its sort key. Disagree with our weighting and you can take the file and weight it yourself — which is what publishing it is for.
The number most people get wrong
The month-six figure. Almost everyone budgets from the first month, which on semaglutide describes four weeks at 0.25 mg — roughly 1 mg of active drug against the 9.6 mg a maintenance month delivers.
Ten of your first twelve months are spent at or near maintenance. A ranking sorted on the advertised month is sorting on about eight per cent of your year, and on a dose-scaled programme those are different numbers entirely.
Run the first-year calculator at the dose you expect to hold. It takes under a minute and it reorders the market for most people.
What a year of this actually looks like
Four weeks at 0.25 mg, four at 0.5 mg, four at 1 mg, four at 1.7 mg, then 2.4 mg for the remainder. Sixteen weeks of titration if nothing is repeated, and repeats are common rather than exceptional.
Budget two extra months at a lower tier and treat anything better as upside. Fix a weekly injection day, record dose and date, and diary the renewal date if an introductory rate applies — the reversion is where most complaints in this category begin.
Why this comparison cannot be settled on price
Only Hims & Hers publishes a price we could capture, at about $2,388 for a first year at a maintenance dose. The other does not. A comparison that filled that gap with an estimate would be inventing the only number that matters.
What can be compared is what each discloses before you pay, and that is frequently the more useful comparison anyway. A programme that names its pharmacy, states its cancellation terms and publishes a price at every dose has told you how it will behave when something goes wrong.
What to do instead
Ask both for the total at 2.4 mg including every fee, in writing, and compare the replies against the programmes that already publish. If one answers in a sentence and the other does not answer at all, you have your comparison.
Why we publish the page anyway
Because the absence is the finding. Someone searching for this pairing deserves to know that one side cannot be priced, rather than being shown a fabricated number or no page at all.
Fee structure, side by side
Hims & Hers charges no recurring fee on top of medication. PlushCare charges no recurring fee.
This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.
Care model and what it buys
Hims & Hers: async, labs optional, included. PlushCare: visit model not published, labs not published, coaching not published.
Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.
Verification, which outranks both
Hims & Hers: brand only since Mar 2026. PlushCare: pharmacy not disclosed.
A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.
What can still be decided here
Without a price on both sides this cannot be settled on cost, so it has to be settled on what each programme publishes — which is frequently the better basis anyway.
Hims & Hers publishes: visit model async, laboratory requirement optional, pharmacy brand only since Mar 2026, cancellation membership recurring. PlushCare publishes: visit model not stated, laboratory requirement not stated, pharmacy not stated, cancellation not stated.
A programme publishing four of those and one publishing none are not equally knowable, and that asymmetry is a finding rather than a gap in our research. Ask both for the total at 2.4 mg including every fee, in writing, and see which answers.
Why a missing price is itself information
A programme that publishes its price is making a claim it can be held to. A programme that reveals cost only after an intake has made a commercial choice: it wants your contact details and a medical history before you can compare it against anything.
That is legal and common. It is also why several pages on this site carry an explanation instead of a number. Estimating would mean inventing the only figure that matters, and every time we have checked an estimate published elsewhere against a provider's own page, the estimate was low.
Putting hims & hers and plushcare in proportion
It is one input into a decision with three parts: what you pay at the dose you hold, who makes what you inject, and what happens if you stop. Weighting one to the exclusion of the others is how people end up on a cheap programme they abandon in month nine.
The frame: 20 programmes publish a capturable price, spanning $145 to $324 a month all-in at a 2.4 mg maintenance dose. 4 charge a mandatory recurring fee. 6 name the dispensing pharmacy before purchase.
What good looks like
A figure at a named dose, the pharmacy named, cancellation terms published before payment, and a plain statement that a compounded preparation is not FDA-approved. Four things, all cheap to publish, and a minority does all four.
The cheapest verified route sits at $145 a month, which establishes that disclosure and low price are not in tension.
What to ask before you pay
Five questions, all answerable in a short email, all before a medical history changes hands: the total at a maintenance dose including every fee; which pharmacy fills it; whether the prescriber is licensed in your state; the notice period to cancel and what is refundable; and which form of the active ingredient the pharmacy compounds from.
None requires clinical training to evaluate. The speed and specificity of the reply tells you how the operation is run, and it arrives before your money does.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.
Common questions
Is Hims & Hers or PlushCare cheaper?
Only one of the two publishes a price we could capture, so this comparison cannot be settled on cost. Both are compared on terms and disclosure instead.
Do Hims & Hers and PlushCare charge a membership on top of medication?
Hims & Hers: no. PlushCare: no. Every figure on this page includes it where charged.
Does Hims & Hers or PlushCare name its dispensing pharmacy?
Hims & Hers: brand only since Mar 2026. PlushCare: not published. It is the disclosure that lets you check a state board register before you inject anything weekly.
Can I switch between them mid-treatment?
Usually yes, after a clinical review. Confirm dose continuity in writing and do not cancel the old programme until the new one has shipped, because a supply gap costs more than a price difference.
Is either Hims & Hers or PlushCare FDA-approved?
Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. Where a programme supplies brand product, that product is approved; the programme around it is not a regulated entity in the same sense.